What is it? Why is it important?

The Sponsor-Investigator (SP-INV) is legally responsible to ensure the:

  • Safety of study participants
  • Quality of study data
  • Traceability of study results

 

To achieve this, a risk-based Quality Management System (QMS), including Quality Assurance (QA) and Quality Control (QC) procedures must be in place.

 

Key elements of a risk-based approach include to:

  • Define the Critical to Quality (CtoQ) factors of the study
  • Identify risks that threaten the integrity of CtoQ factors
  • Evaluate and prioritise risks (i.e. according to a risk-evaluation-matrix that correlates and assesses the likelihood of risk occurrence with risk impact on CtoQ factors)
  • Decide, based on risk evaluation & prioritisation, whether to accept, tolerate, reduce, or eliminate risks
  • Define risk control-measures proportionate to the importance of the data being collected, and safety risks to study participant
  • Defines roles and risk responsibilities
  • Train staff on risk management and risk responsibilities
  • Continuously review and document risk events and the adjustments of risk control-measures

What do I need to do?

As a SP-INV, you are responsible to protect study participants and generate study data able to answer the research question.

 

To achieve this:

  • Apply a “Quality-by-Design” (QbyD) approach to your study, with the aim is to manage risks before they occur
  • Implement a Risk-Based Quality Management System (QMS), focusing on potential risks threatening the integrity of the study`s CtoQ factors
  • When defining CtoQ factors, focus on participant rights and safety (e.g. risk-benefit-ratio), and the quality of study data
  • In a multicentre study, consider regional or local settings. Confer with the Site-INV to identify local risks and quality aspects in need of management
  • Confer with experts supporting the identification of risks to CtoQ factors (e.g. study staff, statistician, quality manager)
  • Define applicable risk control-measures
  • Document the risk management of the study in a Risk Assessment Form (RAT)
  • Maintain and update risk management documents throughout the study, reflecting changes in risk assessment or control

More

Study aim and design should be tailored based on the information needed to answer your research question. The complexity of your study (e.g. design, population) will have a significant effect on potential inherent risks, and the required risk-based-approach needed to control these risks.

 

Excessive activities beyond requirements can overburden staff, extend study milestones and timelines, increase the budget, and the occurrence of risks. Align quality activities proportionally to trial complexity and defined CtoQ factors.

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guideline

  • 2.3 responsibilities
  • 3.10 Quality management

ICH E8(R1) – see in particular

  • 3.1 Quality by Design of clinical studies
  • 3.2 Critical to Quality Factors

ISO 31000 – (access liable to costs) see in particular section

  • Risk management: Principles and guidelines

Swiss Law

ClinO – see in particular article

  • Art. 2 Definitions

Documents

 

Abbreviations
  • ClinO – Clinical Trials Ordinance
  • CtoQ – Critical to Quality
  • CTU – Clinical Trials Unit
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ICH - International Council for Harmonisation
  • ISO – International Organization for Standardization
  • QA – Quality Assurance
  • QC – Quality Control
  • QMS – Quality Management System
  • QbyD – Quality by Design
  • SP-INV – Sponsor-Investigator
Basic ↦ Quality and Risk ↦ Quality Responsibilities ↦ Sponsor-Investigator
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Basic ↦ Quality and Risk ↦ Quality Responsibilities ↦ Sponsor-Investigator